tbuckley/cabot-search huggingface dataset:
Explaining Diarrhea After Vagotomy
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Guide to the Practical Examination of Urine. For the use of physicians and students.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Story of X-Rays from Roentgen to Isotopes.
Journal: Annals of Internal Medicine (1962)

Roentgen gave his great discovery of X-rays to the whole world, but it was so quickly developed by medical science that the average reader tends to forget other applications of the rays.This book is a timely reminder of the many fields into which the use of X-rays has extended.Some of them are less known than others.For example, medical readers do
Studies of the Expression of the Cytochrome P450IA, P450IIB, and P450IIC Gene Family in Extrahepatic and Hepatic Tissues
Authors: Thomas Friedberg, Peter Siegert, Markus A. Grassow, Barbara Bartlomowicz, Franz Oesch
Journal: Environmental Health Perspectives (1990)

We have studied the expression of three P-450 gene subfamilies in hepatic and extrahepatic tissues using the sensitive RNAse A protection assay. Members of the P450IA subfamily, which encodes the major methylcholanthrene-inducible cytochromes P-450, were found to be not expressed in extrahepatic tissues of untreated animals, raising the question whether these P-450 play a role in the metabolism of carcinogens in unexposed individuals. In contrast, members of the P450IIB family, some of which encode the major phenobarbital-inducible cytochromes P-450, were found to be expressed in some extrahepatic tissues of untreated rats and here most notably in the lung and in sebaceous glands. Members of the P450IIC family, which encode some constitutively expressed cytochromes P-450, were found to be expressed exclusively in the liver.
The efficacy of acellular pertussis vaccine
Authors: P. Olin
Journal: JAMA (1989)

<h3>To the Editor.—</h3> Reporting from a workshop at the National Institutes of Health, Bethesda, Md,<sup>1</sup>Mr Marwick stated that "the large Swedish field trial of two acellular pertussis vaccines<sup>2</sup>has not shown levels of efficacy high enough to make either vaccine a likely candidatefor immediate licensure in the United States." We can now report efficacy data from continued surveillance during the posttrial period Aug 27, 1987, to March 20, 1988, to elucidate protection over time and to discuss the effect of surveillance techniques on observed efficacy estimates. All laboratory-confirmed cases of pertussis among children born between March 1985 and September 1985 who participated in the efficacy trial have been identified from laboratory reports to the National Bacteriological Laboratory, Stockholm, and also from spontaneous parental reporting. Study nurses have interviewed parents about the course of illness using questions similar to those used in the main study. The parents
FREQUENCY OF SYPHILIS WITH CANCER OF THE LIPS, TONGUE AND BUCCAL MUCOUS MEMBRANE
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Centers for Disease Control and Prevention. Update: outbreak of Legionnaires' Disease associated with a cruise ship, 1994
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Effects of Aerobic Exercise on Glucose and Counterregulatory Hormone Concentrations in Children With Type 1 Diabetes
Journal: Diabetes Care (2006)

OBJECTIVE—To examine the acute glucose-lowering effects of aerobic exercise in children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS—Fifty children and adolescents with type 1 diabetes (ages 10 to &amp;lt;18 years) were studied during exercise. The 75-min exercise session consisted of four 15-min periods of walking on a treadmill to a target heart rate of 140 bpm and three 5-min rest periods. Blood glucose and plasma glucagon, cortisol, growth hormone, and norepinephrine concentrations were measured before, during, and after exercise. RESULTS—In most subjects (83%), plasma glucose concentration dropped at least 25% from baseline, and 15 (30%) subjects became hypoglycemic (≤60 mg/dl) or were treated for low glucose either during or immediately following the exercise session. The incidence of hypoglycemia and/or treatment for low glucose varied significantly by baseline glucose, occurring in 86 vs. 13 vs. 6% of subjects with baseline values &amp;lt;120, 120–180, and &amp;gt;180 mg/dl, respectively (P &amp;lt; 0.001). Exercise-induced increases in growth hormone and norepinephrine concentrations were marginally higher in subjects whose glucose dropped ≤70 mg/dl. Treatment of hypoglycemia with 15 g of oral glucose resulted in only about a 20-mg/dl rise in glucose concentrations. CONCLUSIONS—In youth with type 1 diabetes, prolonged moderate aerobic exercise results in a consistent reduction in plasma glucose and the frequent occurrence of hypoglycemia when preexercise glucose concentrations are &amp;lt;120 mg/dl. Moreover, treatment with 15 g of oral glucose is often insufficient to reliably treat hypoglycemia during exercise in these youngsters.
SENSITIVITY TESTS FOR CLINICAL CANCER CHEMOTHERAPY
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
Authors: George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Alex Kentsis, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Roland B. Walter
Journal: Journal of Hematology & Oncology (2016)
Méta-analyse comparant les taux de succès de canulation biliaire par sphinctérotomie pancréatique versus précoupe de type papillotomie
Journal: Endoscopy (2017)

Alors que de nombreuses études ont discuté des différentes techniques de canulation utilisées chez les patients avec accès biliaire difficile, aucune méta-analyse n'a comparé la sphinctérotomie transpancréatique (TPS) à d'autres techniques avancées. Les auteurs ont donc mené une méta-analyse identifiant toutes les études comparant efficacité et complications de la TPS versus précoupe (de type papillotomie (NKPP)-technique la plus couramment utilisée.))
Contribution of Reactive Oxygen and Nitrogen Species to Particulate-Induced Lung Injury
Authors: Sha Zhu, Machelle Manuel, Shogo Tanaka, Nonghoon Choe, Elliott Kagan, Sadis Matalon
Journal: Environmental Health Perspectives (1998)

Recently, a second pathway for the generation of potential oxidants with the reactivity of the hydroxyl radical without the need for metal catalysis has been described.In response to various inflammatory stimuli, lung endothelial, alveolar, and airway epithelial cells, as well as activated alveolar macrophages, produce both nitric oxide ('NO) and superoxide anion radicals (02).'NO regulates pulmonary vascular and airway tone and plays an important role in lung host defense against various bacteria.However, 'NO may be cytotoxic by inhibiting critical enzymes such as mitochondrial aconitase and ribonucleotide reductase, by S-nitrosolation of thiol groups, or by binding to their iron-sulfur centers.In addition, 'NO reacts with O2-at a near diffusion-limited rate to form the strong oxidant peroxynitrite (ONOO-, which can nitrate and oxidize key amino acids in various lung proteins such as surfactant protein A, and inhibit their functions.The presence of ONOO-in the lungs of patients with acute respiratory distress syndrome has been demonstrated by measuring levels of nitrotyrosine, the stable product of tyrosine nitration.Various studies have shown that inhalation or intratracheal instillation of various respirable mineral dusts or asbestos fibers increased levels of inducible nitric oxide synthase mRNA.In this presentation, we review the evidence for the upregulation of 'NO in the lungs of animals exposed to mineral particulates and assess the contribution of reactive nitrogen species in the pathogenesis of the resultant lung injury.
Lung Song
Authors: Julie Dunlop
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Future perspectives in physical medicine and rehabilitation
Authors: L. D. Policoff
Journal: JAMA (1966)

The specialty of physical medicine and rehabilitation has almost reached its majority, a 20-year period having elapsed since the founding of its qualifying specialty board. Despite the time lapse and a productive literature, an abysmal ignorance of the true capabilities, viewpoints, and techniques of the practitioners of this specialty and of the specialty itself continues to be widespread. The family physician, the specialist, and the academician seem to share equally a lack of understanding of the specialty of physical medicine and rehabilitation. For this, there would appear to exist a variety of reasons. Perhaps the most significant one is that of psychological orientation. <h3>Attitudes and Approach.—</h3> Physical medicine, and particularly that component of this specialty designated as rehabilitation, has boldly run contrary to the mainstream of medical attitudes as they exist today. This type of approach never makes for popularity. The physician in practice today, the academician teaching in the
SAT0251 Predicting and managing primary and secondary non-response to rituximab using b-cell biomarkers in systemic lupus erythematosus
Authors: MY Md Yusof, D Shaw, YM El-Sherbiny, AC Rawstron, P Emery, EM Vital
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rituximab (RTX) is the most commonly used biologic for the treatment of SLE. However, there is are no clinically applicable predictors of response, which is of particular importance in this heterogeneous disease with other biologics being restricted to certain subgroups. <h3>Objectives</h3> To assess factors associated with primary and secondary non-response to RTX in SLE in order to develop more targeted and effective B-cell therapy. <h3>Methods</h3> A prospective observational study was conducted in 125 SLE patients treated with RTX in Leeds for over 12 years. A major clinical response was defined as improvement of all active BILAG-2004 domains to grade C/better and no A/B flare. Partial responders were defined by 1 persistent BILAG B. B-cell subsets were measured using highly sensitive flow cytometry. Predictors of response were analysed using logistic regression analysis. <h3>Results</h3> 117 patients had evaluable data. In cycle 1 (C1), 96/117 (82%) achieved BILAG response [major=50%,partial=32%]. In MVA, younger age &amp; B-cell depletion at 6 weeks increased the odds of major response (Table 1). Complete depletion was predicted by normal complement &amp; lower pre-RTX plasmablasts. 77 (with data on 72) C1 responders were retreated on clinical relapse. Of these, 61/72 (85%) responded in C2. Of 11 C2 non-responders, 9 met secondary non-depletion non response (2NDNR) criteria, as defined by <i>infusion reaction &amp; defective depletion (</i>incidence=12%) and tested positive for anti-RTX antibodies. Lack of concomitant immunosuppressant &amp; higher pre-RTX plasmablasts predicted 2NDNR. <h3>Conclusions</h3> B-cell subsets should be monitored in the routine care of SLE patients receiving RTX and should aim to achieve complete depletion. About 1 in 8 SLE patients lose depletion on repeat cycles and this is associated with anti-RTX antibodies. Clinical trials using more intensive RTX treatment regimens in those predicted not to completely deplete, or alternatively use of humanised anti-CD20mAbs are likely to increase clinical response rates to B-cell depleting agents. <h3>Acknowledgements</h3> This research was funded/supported by NIHR (DRF-2014–07–155) and (CS-2013–13–032). The views expressed are those of the author(s) &amp; not necessarily those of the NHS, NIHR or the Dept of Health <h3>Disclosure of Interest</h3> None declared
Correction: Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in <i>LAT </i>
Authors: Baerbel Keller, Irina Zaidman, O. Sascha Yousefi, Dov Hershkovitz, Jerry Stein, Susanne Unger, Kristina Schachtrup, Mikael Sigvardsson, Amir A. Kuperman, Avraham Shaag, Wolfgang W. Schamel, Orly Elpeleg, Klaus Warnatz, Polina Stepensky
Journal: The Journal of Experimental Medicine (2017)
Gradients of Maturation and Basic Dye Desorption in Normal and Malignant Cervical Cells
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
Authors: Matthew R. Zibelman, Yu-Ning Wong, Lois Malizzia, Alycia Corrigan, Anthony J. Olszanski, Crystal Shereen Denlinger, Susan K. Roethke, Colleen H. Tetzlaff, Gary R. Hudes, Elizabeth R. Plimack
Journal: Journal of Clinical Oncology (2014)

4568 Background: Elevation of pAKT levels has been shown to result from mTOR inhibition. We hypothesized that the HDAC inhibitor vorinostat (Vori) would abrogate ridaforolimus (Rida) resistance due to down-regulation of pAKT when used in combination in patients with renal cell carcinoma (RCC). Methods: The primary objective was to determine the maximum tolerated dose (MTD) for RCC patients (pts), thus while all solid tumors were allowed, prior cytotoxic chemotherapy was limited to 1 regimen. There was no limit to the number of prior targeted or immunotherapies. ECOG PS 0-1 and adequate organ and marrow function were required. A modified 3+3 dose escalation design tested 2 dose levels concurrently by escalating each drug in separate cohorts. Rida was dosed days 1-5 and Vori days 1-3, weekly. Results: 15 pts (10 clear cell RCC, 3 papillary RCC, 1 esophageal, 1 carcinoid) were treated at 1 of 3 dose levels: 1) Rida 20mg QD + Vori 100mg BID, 2) Rida 20 mg QD + Vori 200 mg BID, 3) Rida 40 mg QD + Vori 100 mg BID. Inability to complete 80% of doses during cycle 1 due to thrombocytopenia resulted in dose limiting toxicities (DLTs) in 2/6 pts at dose level 2. There were no other DLTs and no grade 4-5 toxicities. Related grade 3 toxicities were: hyperglycemia (1), anemia (2), fatigue (1), and mucositis (1). Grade 2 pneumonitis was seen in 2 pts. The MTD was Rida 20mg QD + Vori 100mg BID, however all 7 pts who received >2 cycles required dose reduction to Rida 10-20 mg QD + Vori 100 mg QD, 6 due to thrombocytopenia. Thus the recommended phase II dose (RP2D) to allow for chronic dosing is Rida 20mg QD + Vori 100mg QD. Stable disease for 19, 21, 46+ and 74+ weeks, respectively, was maintained in 4 pts with RCC. Of these, 3 had progressed on prior mTOR therapy, including 2 pts with papillary RCC and ongoing disease control at the time of data cutoff. Conclusions: Rida 20mg QD + Vori 100 mg QD is the RP2D for this combination. Prolonged, ongoing disease control was seen in 2 papillary RCC pts, both of whom had progressed on a prior mTOR inhibitor. Further study of combined mTOR and HDAC inhibition in RCC, with tumor sampling to assess for pharmacodynamics and proof of concept, is warranted to further define the toxicity, efficacy and mechanism of this combination. Clinical trial information: NCT01169532.